Zynex Inc is a medical technology company that specializes in the development and manufacturing of non-invasive medical devices, primarily focused on pain management and rehabilitation
The company's innovative products include electrotherapy devices that utilize neuromuscular electrical stimulation to help patients manage acute and chronic pain, as well as devices designed to aid in physical therapy and recovery. Zynex is committed to improving patient outcomes through its advanced technology and is actively involved in expanding its offerings to meet the growing needs of the healthcare market.
Demand for pain management devices is climbing worldwide, fueled by several major trends. As chronic disease rates soar, the need for effective, drug-free pain solutions has grown more pressing. At the same time, advancements in medical tech have opened doors to safer, non-invasive pain relief options, making them more widely adopted by healthcare providers. Rising numbers of surgeries have also created a strong demand for post-operative pain control, while the pain monitoring market continues to surge. With these combined factors, the global pain management device market is expected to reach $5.68 billion by 2032, expanding at a steady 9% CAGR.
Explore our top picks for short-squeeze stocks that could skyrocket your portfolio. Learn what makes them stand out, and how to spot similar opportunities.
NEW YORK, April 07, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Veradigm Inc. (NASDAQMDRX), LivePerson, Inc. NASDAQ: LPSNNASDAQLPSN)(NYSE: FRCNYSEFRC, and Zynex, Inc. (NASDAQ: ZYXINASDAQ). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
San Diego, CA -- (SBWIRE) -- 04/06/2023 -- An investigation was announced over potential securities laws violations by Zynex, Inc. in connection with certain financial statements.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Zynex, Inc. (“Zynex” or the “Company”) (NASDAQZYXI) on behalf of Zynex stockholders. Our investigation concerns whether Zynex has violated the federal securities laws and/or engaged in other unlawful business practices.
The law firm of Kirby McInerney LLP is investigating potential claims against Zynex, Inc. (“Zynex” or the “Company”) (NASDAQZYXI). The investigation concerns whether Zynex and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zynex, Inc. (NASDAQZYXI) resulting from allegations that Zynex may have issued materially misleading business information to the investing public.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zynex, Inc. (“Zynex” or “the Company”) (NASDAQZYXI) for violations of the securities laws.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zynex, Inc. (“Zynex” or “the Company”) (NASDAQZYXI) for violations of the securities laws.
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQZYXI) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQZYXI) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz announces an investigation of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQZYXI) on behalf of investors concerning the Company’s possible violations of federal securities laws.
